4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
Healthcare
$10.79 +1.70%
+$0.16 today
- Market cap
- $596.08M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
52W Low $3.68High $12.34
Volume 0.81M
Average 0.77M
Income Statement
Follow revenue through to earnings.
Revenue
$85.21M
FY 2025 · Annual
+230194.6% YoYOperating Income
-$159.55M
FY 2025 · Annual
Net Income
-$140.11M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Cost of Revenue | 61.36M | 80.25M | 97.1M | 141.3M | 7.63M |
| Gross Profit | (43.32M) | (77.12M) | (76.37M) | (141.26M) | 77.58M |
| Gross Margin | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| Research & Development | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| Selling, General & Admin | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Operating Expenses | 28.01M | 32.91M | 36.49M | 46.58M | 237.13M |
| Depreciation & Amortization | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBITDA | (69.79M) | (105.09M) | (96.63M) | (154.16M) | (132.48M) |
| EBITDA Margin | -386.9% | -3358.6% | -466.3% | -416656.8% | -155.5% |
| Operating Income | (71.33M) | (110.03M) | (112.87M) | (187.84M) | (159.55M) |
| Operating Margin | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest Income | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Income Before Tax | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Pre-Tax Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Net Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (Basic) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| EPS (Diluted) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| 27.73M | 32.35M | 39.13M | 53.94M | 57.93M | |
| 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
FDMT Earnings Waterfall · TTM
NASDAQ:FDMT · Revenue to Net Income
Key Ratios
EPS$-2.66
Gross Margin-92957.4%
Net Margin-107454.0%
P/E Ratio0.1
P/S Ratio4866.3
Analysis
$88.2M of revenue converted into -$160.9M of net income for the selected period. Gross margin is -92957.4% and net margin is -107454.0%, showing how much revenue survives after costs and taxes. EPS is $-2.66, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 |
How much revenue does FDMT generate?
4D Molecular Therapeutics, Inc. (FDMT) reported $85.21M of revenue in fiscal 2025.
Is FDMT profitable?
4D Molecular Therapeutics, Inc. (FDMT) reported -$140.11M of net income, with a net margin of -164.4%.
Continue the stock analysis
Jump to another research area for this company.